full list rate price target
earn chang report pleas see
tabl page
barclay bank plc and/or affili provid invest bank servic bravo
bidco limit boston scientif corp nyse offer btg lse btg
rate price target estim applic boston scientif corp nyse
previous issu firm research depart temporarili
suspend due potenti transact
book contain background inform possibl question manag
team hope find help prepar upcom meet
med-tech stock outperform
year end decemb healthcar equip suppli
med-tech outperform healthcar
 best-perform healthcar
equip suppli stock ew
laggard includ
remain posit med-tech sector despit valuat
view fundament remain posit sector expect compani
see stabl slightli improv sale growth rate leverag bottom line
valuat high rel basi believ
sustain current level view med-tech repres potenti rel
safe volatil market
updat model reflect recent well latest
think compani end market see tabl page rate
overweight abbott
underweight avano baxter edward lifesci ew
equal weight hill-rom
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
summari rate price target earn chang report chang shown bold
co
barclay research share price target price shown primari list currenc ep estim shown report currenc
current fiscal year estim barclay research fiscal year estim barclay research
valuat methodolog risk
valuat methodolog set price target primarili reli forward price-to-earnings methodolog believ stock
maintain premium multipl given top line bottom line growth prospect pt appli multipl ep
risk may imped achiev barclay research valuat price abbott signific exposur
emerg market given fx rate could pressur ep new product central posit view approv adopt new product
therefor anoth risk risk includ signific reimburs action medic devic product recal fda warn letter
govern regulatori action
valuat methodolog use combin enterpris valu sale price forward earn deriv price target
ev/sal multipl sale estim would impli valuat pe multipl ep estim discount
back rate would impli valuat price target blend two
risk may imped achiev barclay research valuat price risk includ approv
abil compani sustain least mid-single-digit growth time uptak new product abil realiz cost save
target off-set strand cost chang effect tax rate foreign exchang success deploy capit dilut
valuat methodolog set price target primarili reli forward price-to-earnings methodolog pt appli
target pe ep estim
risk may imped achiev barclay research valuat price new product import baxter
growth outlook therefor approv uptak new product key risk factor gener competit particularli cyclo
brevibloc could pressur earn and/or extent pressur less expect favor impact fx rate stronger us dollar
could also pressur baxter sale earn outlook risk includ signific reimburs chang fda govern
co
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli
multipl calendar ep
risk may imped achiev barclay research valuat price upsid risk factor extent becton
success integr bard see greater expect revenue/cost synergi downsid fx stronger us dollar commod
cost could greater headwind risk factor includ time success new product increas competit key product
valuat methodolog risk
drug-coat balloon infus pump signific chang reimburs fda govern action
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target
appli pe multipl ep estim
risk may imped achiev barclay research valuat price fx rate recent acquisit could
pressur earn growth competit pressur particularli area knee competitor launch compet robotic-assist
system could impact growth outlook sentiment toward stock time ultim receipt new product approv could
affect outlook risk includ signific chang reimburs potenti dilut associ acquisit product failur
fda govern action
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli
multipl ep estim
risk may imped achiev barclay research valuat price upsid resolut fda matter
acceler top line growth downsid delay new product approv failur see signific increas new product uptak neg
earn revis addit cost associ on-going manufactur issu risk factor includ signific reimburs chang
competit pressur dilut associ potenti acquisit integr acquir busi proce sale busi
fda govern action
healthcar best perform sector rise versu broader
index within healthcar healthcar equip suppli
med-tech mark anoth year rel out-performance
 healthcar sub-industri rel price perform
best-perform equip suppli stock
ew laggard includ
cover multi-industri analyst julian mitchel cover life scienc tool diagnost analyst meehan cover
 analyst steve valiquett cover
quarterli annual ep usd
consensu number thomson reuter receiv gmt
diversifi growth new product tailwind
rate abbott laboratori overweight price target posit
invest stanc turn follow
favor mix busi past five year abbott manag
intent alter compani product portfolio weight toward
faster-growth higher-margin busi specif abbott divest slower-
growth develop market establish pharmaceut busi acquir st jude
medic today abbott sale attract weight medic devic
nutrit diagnost emerg market establish pharmaceut
abbott sale also attract diversifi geograph perspect
sale unit state sale emerg market
new product cycl sustain above-averag sale growth abbott sale growth rate
acceler past year above-industri growth rate see sever
new product sustain momentum key new product includ
abbott freestyl libr blood glucos monitor devic alin seri diagnost
system abbott host pipelin product well particularli area
double-digit ep growth sustain look ahead continu expect abbott
net incom ep growth outpac sale growth abbott plan continu
pay debt turn drive financi leverag also expect abbott
deliv oper margin expans combin busi mix
merger synergi well cost reduct program believ abbott sustain
constant currenc ep growth low doubl digit next three five year
sale product categori mo
sale geographi
includ nutrit supplement infant children major brand name segment includ pedialit
prevent dehydr pediasur gener pediatr nutrit similac babi formula
includ adult nutrit product specifi meet varieti nutrit goal brand name rang fit
target product like ea protein bar glucerna patient diabet ensur gener adult
diagnost product includ hospit lab clinic instrument system built monitor gener
health help diagnos treat diseas
categori consist system analyz dna rna physician research use treat diseas
identifi specif therapi
point
lab qualiti diagnost test system design rapid portabl includ handheld blood analyz
platform test target avail
abbott brand gener pharmaceut includ therapeut gastroenterolog women health
cardiovascular pain central nervou system respiratori drug vaccin
product includ pacemak system implant defibril cardiac resynchron devic
divis includ product design correct monitor cardiac arrhythmia product includ ablat
cathet gener cardiac map system confirmrx implant cardiac monitor
product divis design monitor treat heart failur product includ heartmat left ventricl
assist devic cardio mem pulmonari arteri sensor
abbott varieti product line includ stent coronari balloon cathet guidewir imag solut
structur heart product includ devic design repair damag heart valv transcathet solut
product includ mitraclip mitral valv repair portico transcathet aortic valv replac amplatz
occlud surgic heart valv
abbott neuromodul devic includ spinal cord stimul treatment chronic pain disord deep
divis includ full product suit treat patient diabet includ glucos monitor test strip
sensor data manag softwar accessori freestyl brand divis also includ abbott
possibl question manag
put take investor consid
investor think long-term growth profil compani
abbott track deliv organ sale growth ep
repres increas
abbott provid earn outlook januari manag made
remark earn call regard outlook manag comment
believ top-lin growth rate sustain higher respect
ep growth manag comment alway start year double-digit goal
manag estim foreign exchang fx like headwind
ep howev plan mitig much possibl
possibl question manag
robert ford heir appar track record abbott
make best candid ceo posit
octob abbott name robert ford presid chief oper offic prior
past three year mr ford execut vice presid medic
devic respons diabet structur heart cardiovascular
neuromodul busi capac mr ford oversaw integr
st jude medic busi mr ford join abbott within diagnost busi
also held posit within nutrit diabet busi
mile white took ceo posit januari time three
candid gener consid duan burnham potenti successor
paul clark oversaw pharmaceut robert parkinson ran intern
mile white ran diagnost busi howev ultim board director
decid appoint mile white ceo robert parkinson parkinson would
later retir abbott effect januari enter academia briefli
resurfac baxter ceo manag team structur reorgan
parkinson departur abbott anoth richard gonzalez took
posit march decemb
possibl question manag
investor think manag alloc capit near
intermedi term optim leverag level
current thought
would pro con spin nutrit establish
pharmaceut busi medic devic diagnost franchis
would will sell one
financ st jude medic aler acquisit abbott issu signific amount
debt total debt reach high billion decemb
cours compani significantli de-lev septemb
abbott nearli billion total debt billion cash equival
reflect net debt billion howev reflect abbott issuanc
approxim billion euro debt septemb subsequ octob
use proce redeem approxim billion higher interest rate debt
matur rang bring total debt billion sever
compani also restructur debt includ euro debt lower interest
respect abbott comment call alway keep ear
ground hasnt seen anyth draw attent doesnt
anyth radar screen think benefici rather continu priorit
invest spend intern build capac freestyl libr
expans alin
possibl question manag
launch freestyl libr progress unit state rel
origin expect
comment recent prescript rate attrit rate
roll-out freestyl libr perform europ major
market rel expect
see long-term market opportun freestyl libr
roll-out freestyl libr europ receiv
expect freestyl libr and/or iter come unit state
view verili miniatur continu glucos
monitor program could risk longer term freestyl libr
similar effort underway
abbott diabet busi repres total sale product includ tradit blood
glucos monitor meter test trip continu blood glucos product market
freestyl brand
freestyl libr continu glucos monitor cgm system includ handheld
reader dispos sensor worn back upper arm fingerstick
calibr requir abbott first launch freestyl libr system europ
sensor system approv us fda septemb
sensor system approv us fda juli octob abbott receiv
ce mark european approv freestyl libr add option real-tim alarm
function lack real-tim alarm view competit
disadvantag rel cgm system market would expect abbott pursu
approv freestyl libr unit state abbott also evalu use
pediatr patient product current approv adult year older
freestyl libr system use million peopl diabet
global countri last year sale total around million
year estim sale like around billion view freestyl libr
potenti multi-billion dollar product abbott next sever year
compani continu grow intern proce roll-out unit
cgm system avail market includ
dexcom latest gener cgm system receiv fda approv march
devic provid real-tim glucos inform everi five minut
read period sensor worn day system
requir fingerstick calibr treatment decis made without
confirmatori fingerstick expect revenu approxim million
full year
medtron guardian connect cgm commerci launch june
cgm sensor worn day devic also take sensor
glucos read everi hour unlik dexcom abbott freestyl libr
guardian connect cgm system indic adjunct devic complement
replac inform obtain standard blood glucos monitor devic
devic also requir calibr everi hour work get label
fingerstick
eversens cgm includ profession insert implant
sensor place upper arm last month system approv
june glucos data automat sent everi minut mobil app
user smartphon system requir fingerstick calibr intend
complement replac fingerstick blood glucos monitor
look ahead player look iter technolog verili
work togeth develop miniatur continu glucos monitor vision
make miniatur sensor electron adhes patch
possibl question manag
would describ competit posit alin rel
major manufactur introduc new system
experi date european/intern roll-out
alin famili diagnost system extent alin mix
discuss plan alin roll-out unit state
abbott diagnost divis repres total sale includ core laboratori
system molecular diagnost system point care system rapid diagnost
system product gener sold blood bank hospit commerci lab
clinic physician offic govern agenc altern care test site plasma
alin diagnost system integr famili next-gener diagnost system
solut intern market abbott roll alin clinic
chemistri alin immunoassay diagnost alin blood plasma
screen late abbott receiv fda approv alin alin
system await approv critic mass assay execut fulli
roll-out plan alin molecular diagnost approv use europ
expect approv us late collect believ system
launch sustain improv upon abbott mid-single-digit diagnost sale growth
possibl question manag
new product within structur heart busi excit
see potenti growth rate structur heart franchis
next year
expect receiv expand indic mitraclip base
coapt data expect see acceler growth thereaft
expect us approv portico strategi
launch given youll fourth entrant market would will
price aggress
current statu on-going clinic trial tendyn
believ transept deliveri ultim requir commerci success
current statu amplatz amulet program
anticip time us approv
abbott structur heart franchis today repres approxim sale
includ product mitraclip percutan mitral valv repair system tissu
mechan surgic heart valv amplatz occlud portico transcathet
aortic valv look ahead number new er product and/or indic
expans could fuel futur growth
mitraclip transcathet mitral valv repair system approv sinc march
europ sinc octob us us approv limit
patient signific symptomat primari degen mitral regurgit
septemb result coapt studi releas show significantli
lower rate hospit heart failur all-caus mortal month
compar medic therapi alon data file fda support
expand indic includ patient moderate-to-sever sever secondari
function mitral regurgit mitraclip sale approxim million
believ track achiev roughli million coapt result
doubl tripl address popul today abbott estim
us alon put total address market valu excess billion
portico abbott acquir portico transcathet aortic valv replac tavr
devic st jude medic acquisit portico valv size receiv
ce mark european approv novemb addit size subsequ
approv decemb septemb one-
year result portico studi real-world analysi present last septemb
year kaplan-mei estim all-caus mortal cardiovascular mortal
disabl stroke rate myocardi infarct
respect paravalvular leakag moder higher patient
sever leakag new pacemak rate pacemak nave
patient day year respect abbott us pivot trial data expect
releas american colleg cardiolog march portico
trial includ approxim high risk extrem risk patient random
either portico valv commerci avail valv edward sapien
medtron corevalve/evolut abbott also evalu next-gener flexnav
deliveri system addit patient abbott plan launch portico
unit state earli estim portico valv sale current
million rang favor us clinic trial data us launch would help expand
abbott share billion tavr market
tendyn mitral valv replac program acquir abbott august
devic evalu treatment symptomat sever mitral
regurgit ce mark trial enrol complet abbott expect launch
system earli europ respect unit state market juli
abbott receiv fda approv begin pivot summit trial evalu
tendyn mitral valv patient mitral regurgit patient
studi random ratio tendyn devic convent mitral
valv surgeri primari endpoint composit endpoint death cardiovascular
hospit stroke reoper one year would anticip trial
could take two year enrol put data read-out late approv
possibl
tricuspid valv repair august abbott initi enrol trilumin
ce mark trial clip-bas transcathet tricuspid repair system build
mitraclip system studi evalu symptomat patient site
unit state europ primari endpoint echocardiograph tricuspid
regurgit reduct grade day procedur
assess major advers event month abbott expect complet trial
late ce mark european approv late us pivot trial expect
begin abbott estim roughli million undertr patient
eu us make anoth potenti larg market opportun
mark approv januari us clinic trial amplatz amulet
initi septemb trial random patient either amplatz
amulet devic boston scientif watchman laa closur devic control
group enrol expect complet earli follow-up
complet sometim late would put potenti fda approv
second half estim left atrial appendag market roughli
million size today potenti grow billion given number
patient atrial fibril
possibl question manag
rate expect vascular busi grow next
year given current product competit market
plan differenti surveil dcb market place
feel need add addit product gain greater scale
stand develop percutan heart pump
php product still tri develop
abbott vascular busi account total compani sale includ
xienc famili drug-elut coronari stent coronari balloon dilat product
guidewir starclos se perclos proglid vessel closur devic supera
peripher stent system carotid stent imag cathet well pressurewir ffr
drug-coat balloon februari abbott announc sign
agreement wherebi abbott obtain exclus world-wide
commerci right surveil drug-coat balloon ce mark european
approv expect around year end surveil current studi
transcend pivot trial enrol trial random patient
receiv either surveil dcb pact admir dcb primari
efficaci endpoint trial primari patenc defin composit freedom
restenosi clinically-driven target lesion revascular tlr month
post-index procedur surmod expect trial enrol run septemb
would put result read-out late potenti approv
addit surveil dcb abbott also receiv option negoti
agreement below-the-kne arterioven av fistula drug-coat
balloon product estim drug-coat balloon market million
market categori becton dickinson leader
capabl expand billion
percutan heart php heartmat php percutan heart pump
design deliv blood flow mean flow stabil
european approv juli support patient undergo high-risk
percutan coronari intervent pci shield ii us pivot trial initi
howev abbott identifi small number clinic event associ
pump stoppag support high risk pci patient clinic commerci
use prompt abbott halt studi european sale abbott
evalu design modif still pursu develop devic
though timelin indic market hemodynam support
product measur billion abiom impella lead product sale
expect compani rang million fiscal
possibl question manag
chang made within neuromodul commerci
effort order return segment double-digit growth
key product develop area neuromodul
abbott neuromodul busi account total sale includ spinal cord
stimul proclaim elit prodigi mri proclaim drg design dorsal root
ganglion therapi infin deep brain stimul treatment
movement disord past coupl quarter abbott growth slow
singl digit compani lost share
possibl question manag
nutrit busi sustain current level growth
forese busi track longer term
abbott nutrit divis total sale includ pediatr adult nutrit
product brand market abbott includ similac infant formula isomil
nutrit zone perfect bar adult nutrit myoplex adult nutrit advantedg
adult nutrit product gener sold consum well institut
wholesal retail healthcar facil govern agenc
time spin-off nutrit busi consid driver
sale profit growth busi gener sale growth
respect sale growth slow period
respect abbott face headwind intern market
china first nine month abbott nutrit busi reflect
solid growth pediatr adult
possibl question manag
level confid sustain growth mid-to-high
sensit epd market macro econom trend individu
abbott establish pharmaceut divis epd total sale market
extens portfolio brand gener pharmaceut emerg market focu
key market india russia china brazil abbott five broad therapeut
area focu gastroenterolog product women health product cardiovascular
metabol product pain central nervou system product respiratori
drug vaccin brand gener drug gener sold directli wholesal
distributor govern agenc health care facil pharmaci independ
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight view abbott high-qual
growth asset believ compani
favor mix busi product
geograph perspect see medic devic
busi key driver growth go forward
believ growth profil warrant premium
upsid case depend sever key factor
approv new product greater traction new
product success integr st jude
aler busi stable-to-improv trend
downsid case driven foreign
exchang rate slowdown emerg market
growth inabl receiv product approv
quarterli annual ep usd
consensu number thomson reuter receiv gmt
rate underweight price target cautiou
stanc turn follow
 ip divestitur provid rebirth compani divestitur surgic
 infect prevent ip asset avano lost halyard brand also
albatross around compani neck growth perspect see sale
posit believ manag team right strategi redeploy
 ip proce medic devic growth initi
howev believ risk on-q franchis growth outlook
avano on-q pain pump face challeng owe disrupt
pump filler well drug shortag expect dynam continu
also see potenti increas competit potenti new pharmaceut
total compani sale thu meaning product compani see
earn risk well well believ achiev state long-rang plan may
challeng anticip
believ avano stori like turn futur avano plan use
proce ip sale fund futur acquisit think wise
strategi enhanc compani exposur better end market said
there still risk valuat ultim paid asset compani
abil success execut deal
sale product categori
sale geographi
chronic includ digest health feed solut product along respiratori health product
design chronic care patient brand divis includ mic-key enter feed tube kit feed
solut corpak acquisit ballard airway suction system
pain manag two main franchis acut pain product estim account roughli
two-third total pain manag sale estim sale on-q surgic pain pump
busi remaind iv therapi intervent pain solut account remain
one-third sale includ compani coolief system minim invas water-cool radio-frequ
treatment chronic pain avano ad pain manag franchis juli acquisit
coolsystem game readi game readi offer pain manag rehabilit product orthoped
surgeri patient patient sport relat injuri major product includ grpro cold compress
system atx wrap
chronic barclay medic suppli devic
possibl question manag
see core compet greatest strength
compani convers see greatest weak
plan address
see compani strategi unfold next sever year
might avano look like year
thought would prefer multipl
smaller-s tuck-in deal larger transform acquisit
formerli halyard health product strategi shift spin-off
divestitur halyard health form spin-off corpor
healthcar busi octob spin-off halyard
strategi stand-alone compani remain focus shift mix toward higher
growth margin medic devic busi surgic infect prevent ip
segment consist struggl price eros input cost volatil offset
much growth come medic devic segment june woodi
took helm halyard focus remain medic devic segment
novemb halyard announc sale ip busi owen minor
deal close april effect june halyard health chang name
avano medic inc sold name halyard health owen minor
sole focus medic devic focu pain manag chronic care
avano sold ip busi total purchas price million net proce
approxim million avano use proce million retir
remain portion senior secur loan manag intend invest remain
proce back busi acquisit organ growth manag
estim follow ip divestitur million acquisit
capac moreov manag comment focu acquisit leverag
exist technolog expand call point increas address market
first deploy capit juli acquisit coolsystem inc
market game readi game readi total consider million game
readi revenu approxim million result price sale
valuat nearli revenu game readi market-lead provid cold
therapi compress therapi system market primarili orthopaed sport
injury-rel end market avano intend leverag game readi strong orthoped
surgeon relationship continu increas on-q penetr orthoped procedur
manag comment game readi perfect exampl approach
insofar complementari acquisit expand portfolio well sale
channel call point expect manag continu look corpak game
readi type deal though would necessarili rule larger deal could
transform manag also comment transform deal could
septemb avano million cash restrict cash
million debt
possibl question manag
put take investor consid
signific headwind issu on-q expect
investor think long-term growth profil compani
still feel confid long-rang plan
follow releas result avano manag team reduc sale
forecast balanc year mainli reflect reduc
expect acut pain busi due drug shortag affect on-q busi
also distributor stock pattern pain manag chronic
manag re-affirmed adjust ep rang includ earn
divest ip busi first part year
intend
january/februari drug shortag regulatori headwind expect continu
like pressur sale earn outlook avano also
continu feel million dis-synergi relat ip divestitur expect
partial off-set million cost-sav initi
report result
avano laid long-rang plan investor day june
plan illustr figur forecast acceler top-lin growth mid-singl
high-singl digit along improv profit
avano long rang lrp issu june
embed within assumpt improv margin avano cost transform
program avano estim left approxim million dis-
synergi follow ip divestitur repres cost previous alloc across
 ip medic devic segment cost sole alloc
remain medic devic busi avano intend off-set strand
cost million annual save save expect come
gener organ right-siz
distribut network suppli chain procur save well
continu program zero-bas budget lean manufactur
on-q pump challeng competit outlook
possibl question manag
latest think shortag bupivacaine/ropivacain
potenti impact
partnership leiter ramp relationship key
feel on-q posit rel pacira exparel
ad outpati reimburs present potenti headwind on-q
view heron therapeut potenti risk
may pose on-q franchis could similar exparel launch
avano on-q pain relief ambulatori pain pump provid pain relief
five day on-q balloon-typ pump fill local anesthet
deliv cathet place near surgic site physician roughli
on-q sale relat orthoped procedur pump also use
cardiovascular cardiothorac urolog gynecolog obstetr gener surgic
procedur pump program infus local anesthet steadi rate
model allow patient control dose level drug use includ
ropivacain use time bupivacain pump predominantli use
inpati set
avano on-q franchis face challeng past sever quarter two
reasonsshortag bupivacain ropivacain well issu pump filler
avano first note drug shortag reason behind slower-than-expect on-q sale
confer call healthcar facil face shortag anesthet
agent one industri largest drug manufactur on-going
manufactur issu legaci hospira facil hospira struggl maintain proper
manufactur receiv numer warn letter hundr product recal
last decad macpherson kansa plant product site bupivacain
ropivacain receiv fda warn letter februari june
fda inform complet evalu correct action close
warn letter determin violat address also
challeng bupivacain rocki mount nc site
fda drug shortag databas current list ropivacain bupivacain
shortag past sever month suppli avail ropivacain
improv manufactur report current avail bupivacain current
backord list major manufactur freseniu kabi
auromed backord shortag expect continu least
june mani present bupivacain
on-q pump either fill pump filler hospit avano initi
challeng suppli perspect two larger pump filler
locat houston disrupt due hurrican fall
earli pump filler pharmedium/amerisourcebergen unabl fill pump due
find fda audit subsequ shut juli avano
announc prefer provid relationship leiter fda-regist
outsourc provid fill on-q
avano also face competit non-opioid product post-op pain
relief today exparel approv fda use treat post-surg pain
drug expect come market one closest
approv potenti approv april also compani
work non-opioid drug altern
exparel bupivacain liposom inject suspens administ surgic
site time surgeri control pain exparel use pacira proprietari depofoam
deliveri technolog encapsul drug without chang molecular structur
releas desir period time exparel commerci launch
unit state april novemb center medicar
medicaid servic final polici provid separ reimburs
exparel administ ambulatori surgic center asc pay
exparel averag sale price asp code go effect januari
favor data publish recent exparel
novemb studi publish on-line journal medic econom
conclud use exparel manag postsurg pain follow tka
lead reduct opioid use length stay total hospit cost compar
patient receiv exparel convers studi publish
journal may cast neg light on-q
studi conclud use continu pain pump case on-q pump
follow total knee arthroplasti tka lead longer length stay well
decreas ambul post-operative day one
heron develop use biochronom drug deliveri
technolog extended-releas formul bupivacain meloxicam htx-
design deliv pain relief hour shown reduc
pain compar bupivacain placebo hernia repair bunionectomi total knee
arthroplasti abdominoplasti breast augment grant track
breakthrough therapi design fda compani submit new drug
applic nda fda fda grant pdufa date april
heron anticip lunch around mid-year
taiwan liposom co ltd tlc develop treatment post-surg
pain manag bioseiz formul ropivacain tlc bioseiz
lipid formul technolog design enabl local sustain releas fast
onset activ pharmaceut ingredi api tlc submit investig new
drug ind applic fda april recruit dose
patient inguin hernia repair phase i/ii dose-escal trial us top-line
data expect first half
impact treatment liposom bupivacain hospit cost length stay discharg statu patient
undergo total knee arthroplasti high-us institut journal medic econom doi
on-q infus pump link increas hospit stay total knee arthroplasti stephen oneil kristoph
possibl question manag
comfort double-digit sale growth profil coolief
meaning could upcom data releas coolief
discuss current futur reimburs environ
avano compet radiofrequ rf ablat segment coolief rf
ablat technolog tradit rf ablat minim invas procedur use
thermal energi heat destroy nerv fiber stop transmiss pain signal
brain coolief differenti standard rf treatment use water-
cool technolog instead heat gener energi use heat limit amount
rf energi abl deliv given time therebi limit effect standard
rf treatment shape lesion use thermal energi also ellipt
necessit probe place parallel target nerv order success
ablat nerv fiber use cool rf technolog allow addit rf energi
creat lesion volum thermal rf lesion shape spheric
allow physician approach target nerv perpendicularli well parallel
combin allow success rf treatment
rf proven provid pain relief far month current almost
entir use treat chronic spine pain knee hip pain compris
procedur volum respect avanoss coolief market share leader
estim sale grown compound-annual-growth-rate
coolief receiv fda approv manag chronic osteoarthr oa knee
pain april coolief remain rf ablat treatment approv
treatment chronic moder sever knee pain caus osteoarthr indic
expans knee pain provid increment million patient popul
coolief though reimburs remain challeng avano current recruit
studi compar efficaci coolief vs hyaluron acid ha intend initi
studi versu tradit rf ablat well studi vs ha expect enrol
patient evalu proport subject greater equal pain
reduct six month measur advers event month accord
clinicaltri gov studi expect complet data collect primari outcom
measur april data favor could help drive sale growth
acceler worth note though could hesit refer
patient orthoped doctor inject drug would like refer
patient elsewher intervent pain manag specialist get coolief
coolief reimburs profil today larg hospit expect
institut separ code cover new procedur rf nerv ablat januari
either acut ambulatori surgic center offic set chronic pain due
oa knee level reimburs associ code remain
uncertain improv reimburs environ could lead meaning uptak
procedur treat osteoarthritis-rel knee pain
possibl question manag
larg oral care busi signific share loss
quantifi impact distributor purchas time oral
estim chronic busi gener million revenu
includ two sub-seg respiratori digest
respiratori health busi focus support patient ventil
specif reduc occurr ventilator-associ pneumonia vap
product includ microcuff endotrach tube ballard close suction system
avano digest health busi focus enter feed market enter feed
requir patient function gastrointestin gi tract swallow
digest food normal lead malnutrit
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight view sale ip
posit catalyst believ compani
right strategi redeploy ip proce
medic devic growth initi howev
believ risk on-q franchis
may pressur earn leav compani short
lrp goal rate underweight
upsid case could driven greater sale
 lead improv outlook
greater recoveri on-q busi drug
downsid case could driven deceler
sale growth trend inabl achiev cost
save unsuccess intensifi drug
shortag could pressur on-q sale
new pain drug approvals/competit
quarterli annual ep usd
consensu number thomson reuter receiv gmt
rate underweight price target invest
stanc turn follow
signific stride made sinc baxalta spin-off sinc spin-off
bioscienc baxalta appoint almeida ceo
januari baxter significantli improv margin cash flow
signific stride still come baxter expect sale growth acceler
long-rang plan lrp averag compound-annual-growth-rate
baxter expect oper margin expand
turn lead robust ep growth lrp period
howev think market high expect see risk ahead
past two year baxter consist beat-and-rais stori believ
market expect beyond may high baxter rais
guidanc throughout year consequ street model higher
expect beyond howev believ factor benefit
like repeat gener competit cyclo brevibloc fda
warn letter relat clari fx higher tax rate could headwind near
term ep estim refinitiv estim
sale product categori mo
sale geographi mo
divis includ product patient chronic kidney diseas end-stag renal diseas compani make
product periton dialysi in-hom hemodialysi in-cent well remot patient monitor
devic design icu patient need organ support includ prismax continu renal replac
therapi crrt patient acut kidney injuri
product includ iv medic infus system drug reconstitut devic baxter infus pump
divis includ baxter pre-mix inject oncolog drug anesthesia specialti pharmaceut
nutrit divis includ parenter intraven nutrit solut pre-matur babi chemotherapi
patient chronic ill patient patient recov surgeri baxter offer premix nutrit
balanc formula provid manag compound technolog meet uniqu patient need
surgic care product design reduc bleed heal tissu prevent adhes procedur
product includ floseal hemostat matrix product part acquisit
recothrom topic thrombin preveleak surgic sealant
baxter categori includ revenu pharmaceut product baxter manufactur behalf
possibl question manag
put take investor consid
investor think long-term growth profil compani
key risk
pipelin product manag confid area
carri greatest risk
manag still confid achiev long-rang plan target
manag less confid achiev sale
growth target manag cost structur achiev target ep
may baxter host bi-annu investor meet provid updat
financi outlook baxter expect sale growth acceler lrp period sale
averag acceler period
contribut new product geograph expans new product
expect account growth long-rang plan term new
product sale divis expect contribut
million follow renal medic deliv million new contribut
also expect acut therapi million clinic nutrit million
advanc surgeri million
baxter expect see continu oper margin expans driven cost
reduct importantli product mix specif baxter expect oper
margin reach expand adjust ep
expect expand oper cash flow free cash flow
expect increas billion billion respect summari
lrp illustr figur
possibl question manag
investor interpret recent comment investor
present earn call regard acquisit
area adjac manag believ offer greatest
opportun
would manag will acquisit white space
baxter signific capit flexibl baxter expect gener billion
free cash flow increas billion nearli billion
septemb baxter billion cash equival billion total
debt leas oblig net debt million
term capit alloc philosophi manag comment start
reinvest busi deliv exceed plan extent increment
idea capit equip standpoint help acceler growth look
properli fund second prioriti fund dividend rais
last sever year goal move pay-out ratio balanc
 versu share buy-back manag focu asset
attract market grow baxter growth rate consid return
invest capit import metric want robust return invest
capit year manag note believ logic
baxter own asset plug directli sale forc build onto
and/or compet baxter bring tabl allow extract valu
uniqu way versu other compet compani build cost
transform note size never import factor
sinc spin-off baxalta baxter done transact largest
transact acquisit clari inject limit approxim million
net cash clari ad capabl product gener inject medicin
anesthesia analges renal anti-infect critic care varieti
present includ bag vial ampoul march baxter acquir two
hemostat sealant product recomthrom preveleak
up-front payment million subsequ paid million post-clos
possibl question manag
manag gain comfort long-rang plan forecast
given perform busi full year guidanc low
manag see futur growth rate infus solut
small volum
manag see expect uptick
parenter suppli avail
confid manag new pump opportun
geograph region feel confid abil gain share
baxter medic deliveri busi account total compani sale roughli
two-third busi intraven iv therapi solut remain
third infus system sigma spectrum infus pump iv set market
product oligopoli intraven therapi three main iv solut
compani baxter icu medic braun freseniu kabi also manufactur iv
solut mainli outsid unit state infus system three main
competitor includ becton dickinson icu medic baxter infus system
manufactur includ braun smith medic smith group end market
estim grow around year
past five year us market infus solut suppli
challeng particularli area larg volum parenter lvp includ normal salin
dextros fda drug shortag websit note sodium chlorid
inject bag shortag start januari product remain shortag
condit qualiti control problem one reason capac constraint
baxter hurrican maria impact puerto rico facil also caus signific
disrupt particularli small volum parenter svp solut svp solut
volum ml less design reconstitut activ pharmaceut ingredi api
administ intraven baxter svp includ mini-bag mini-
help eas constraint fda approv shipment facil outsid
unit state baxter abl sourc product ireland australia mexico brazil
baxter receiv perman approv fda increas shipment larg
volum iv solut mexico baxter also abl realloc addit iv
solut volum select south american manufactur facil expect
action allow complet remedi activ modern product
process certain manufactur facil puerto rico fda also
allow braun import product foreign facil allow freseniu grifol
import us well
baxter medic deliveri busi disappoint larg due infus
solut busi sale lvp increas significantli thank addit
volum product mexico help off-set impact hurrican maria
svp side strength busi baxter rais guidanc
howev baxter subsequ lower guidanc twice busi
follow result declin low singl digit follow result
baxter note take longer expect gain new custom follow
improv lvp suppli continu see suppli constraint svp
manag note believ lvp stock took place earlier
year initi expect part driven flu inventori level need
work also note take longer expect see custom
return use svp move use iv push administr drug
well competit product manag express busi go
rebas long-rang plan period growth goal
still achiev
busi seen share challeng past baxter use lead
infus pump leader colleagu platform howev colleagu
histori issu recal ultim led compani put consent
decre fda fda-mand recal remov
market baxter requir either swap pump new oneit
acquir sigma spectrum pumpor offer money hospit entiti purchas
new one baxter acquir stake sigma ultim acquir
remain stake baxter alon pump problem then-cardin
health carefus unit part then-hospira part icu
medic also pump recal challeng past net/net baxter end lose
roughli half market share time biggest beneficiari becton
baxter set sight recaptur infus pump market share us global
us baxter receiv fda clearanc may latest-gener spectrum
pump spectrum iq dose iq safeti softwar spectrum iq design
broad rang auto-program workflow featur set well embed on-
integr outsid unit state baxter aim captur share launch
evo iq infus receiv ce mark regulatori approv uk ireland
australia new zealand august commerci launch activ slate
begin baxter also look launch first syring pump evo iq syring
baxter believ critic success emea latin america
baxter work develop new global pump platform bring togeth
technolog area larg volum pump syring pump pain manag devic
integr back end
possibl question manag
latest updat fda warn letter relat clari
see potenti
impact gener competit
cyclophosphamid brevibloc would quantifi potenti
give confid abil grow busi lrp rate
period key new product
drive growth
baxter pharmaceut busi repres approxim total compani sale
pharmaceut includ three categori product gener inject drug
inhal anesethesia sale drug compound
cylco brevibloc togeth estim rang million
two drug see gener eros
baxter cyclophosphamid cylco immunosuppress chemotherapi
agent sandoz launch first gener version product novemb sinc
baxter seen sale cyclo declin million peak
expect million howev pace eros slower
expect gener competit thu far limit baxter initi
guidanc call million sale million though sale
end year total million baxter initi guidanc million
sinc increas forecast million may amneal
pharmaceut announc fda approv anda cyclophosphamid
impact appear quit limit
baxter brevibloc beta blocker sale total approxim million
baxter benefit competitor issu sale came higher
manag anticip go forward howev baxter like see
eros breviloc sale face gener version approv
septemb gener manufactur also approv list
therapeut equival fda
baxter broaden gener inject busi juli acquisit clari
inject limit approxim million net cash clari ad capabl
product gener inject medicin anesthesia analges renal
anti-infect critic care varieti present includ bag vial
ampoul baxter expect clari contribut approxim million sale
long-rang plan baxter expect busi
provid largest million new product contribut expect increas
number molecul number new product
lrp clari signific contributor new product manag expect
add molecul per year period molecul per
year period howev clari receiv warn letter juli
regard violat current good manufactur practic cgmp regul
ahmedabad india facil fda start inspect day baxter acquir
compani violat correct complianc cgmp confirm fda
may withhold approv new applic supplement list compani
baxter also enter exclus strateg partnership gener oncolog inject
scinopharm taiwan februari scinopharm activ pharmaceut
ingredi api manufactur term agreement two parti
develop manufactur baxter hold commerci right five inject
drug arrang also provid baxter option partner scinopharm
mani addit inject molecul product expect launch
begin accord baxter time announc brand sale
initi five product total billion
possibl question manag
level uptick investor expect kayuga launch japan
manag see market opportun theranova
signific manag view point solut
expect timelin launch
baxter renal busi repres total sale third busi
periton dialysi product remain third hemodialysi product
three main form dialysi therapi today hemodialysi hd home
hemodialysi hhd periton dialysi pd new patient annual incid
nearli hd nearli pd leav less place hhd total
popul preval hd pd nearli hhd
hemodialysi hd perform dialysi center freseniu medic
healthcar partner control market term center
hd blood remov bodi set tube run
filter dialyz remov impur return back bodi
individu undergo treatment three time week session four hour
long freseniu lead manufactur hd dialyz player includ
baxter nipro medic asahi kasei nikkiso braun
hemodialysi hhd perform patient home essenti
process hd hhd treatment plan vari often five six time week
session last hour nxstage pend acquisit freseniu sell
periton dialysi pd differ approach use tube place
abdomin caviti allow dialysi exchang dialysi fluid pd solut
done night use pd cycler machin day
manual exchang typic last minut patient usual go clinic
month baxter lead provid pd freseniu also sell pd solut
system nxstage also develop periton dialysi system
underweight believ baxter pois
drive sale growth acceler new
product launch howev believ
consensu expect high see
earn risk competit gener launch
inabl launch pharma product due
warn letter higher tax rate fx ep
estim street
upsid case could driven gener
competit less expect greater
success bring new product market
greater-than-expect improv profit
downsid case could driven greater-
than-expect cyclo brevibloc sale
competit pressur renal medic
deliveri foreign exchang rate
strengthen us dollar
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
co quarterli annual ep usd
consensu number thomson reuter receiv gmt
rate equal weight price target invest
stanc turn follow
posit fundament outlook addit bard believ becton
dickinson posit consist top-lin growth compani
also see opportun margin expans realiz cost synergi
relat bard acquisit on-going cost optim effort product mix
top line growth prospect margin expans potenti financi leverag
compani pay debt allow becton dickinson sustain adjust
ep growth doubl digit
carefus integr went well leav market high hope bard
becton acquir carefus integr went well
rais amount deal cost synergi believ market expect becton
likewis rais cost synergi target bard though dont believ
materi near term
fiscal back-end load see risk fiscal forecast
expect becton dickinson fiscal result skew second half
own difficult comparison due flu year ago period well
pull-forward revenu occur look beyond
believ fiscal street forecast may high gore royalti incom come
end repres headwind ep growth ep estim
street
sale duct categori forma
sale geographi forma
insert venou cathet midlin cathet port access central line peripher insert central cathet
iv connector extens set iv fluid closed-system drug transfer devic hazard drug detect
convent safeti hypoderm syring needl anesthesia needl spinal epidur tray enter
busi includ two main franchis includ infus pump dedic dispos
medic suppli manag system
diabet product includ insulin pen needl syring product infus inject
product includ prefil syring self-inject system safeti shield system sold
pharmaceut compani use contain inject pharmaceut product
product collect blood specimen analysi bd vacutain blood collect
molecular diagnost test system autom cultur system rapid diagnost assay women health
screen test brand name includ bd molecular test system bd surepath cervic cancer screen
instrument reagent diagnost system bd fac product line cell analyz sort
cytometri kiestra lab autom system antibodi immunolog reagent fluoresc dye
hernia soft tissu repair biolog graft bioresorb graft biosurgeri surgic product
bdchloraprep surgic infect prevent product thorac abdomin drainag product mueller
surgic laparoscop instrument product
vascular stent self-expand balloon-expand stent graft vascular graft port biopsi chronic dialysi
feed filter endovascular fistula creation devic drainag product
urolog drainag product intermitt cathet urinari fecal manag devic kidney stone
manag devic target temperatur manag
possibl question manag
divis feel least confid top-lin growth
given recent move oil price could resin cost less guidanc
would expect lag
gore royalti run-rat higher acquir bard still
feel comfort grow mid-teen mid-teen goal
adjust number exclud impact gore royalti
investor think long-term growth profil compani
outlook guid top mid-teen ep
growth look beyond bd top line
prior bard acquisit novemb manag expect
deliv sale ep growth period april
announc bard transact manag updat longer-rang forecast
inclus bard becton manag expect sale growth
annual oper margin expans mid-teen ep growth period
fiscal becton compar currenc sale growth chang
revenu recognit dispens impact hurrican repres
headwind sale acquisit stronger flu season time sale
tailwind thu net/net becton underli sale growth mid-point
long-rang target bd ep grew constant currenc though
estim underli ep growth closer adjust dispens
chang impact divestitur non-bard acquisit
novemb becton dickinson provid initi guidanc fiscal becton
expect compar constant currenc revenu growth adjust
acquisit divestitur portfolio realign divis becton expect compar
constant currenc revenu growth medic life scienc
reflect tougher flu comp intervent report basi sale
expect increas inclus headwind fx becton expect
ep year-over-year report basi reflect
underli growth plu benefit lower tax rate off-set
higher raw materi cost tariff tougher flu comp
divestitur fx
look beyond fiscal becton face difficult comparison royalti
current receiv gore attribut legaci bard busi ceas
august royalti current annual north million howev end
august expect contribut roughli million fiscal estim
repres per share earn headwind becton
manag comment abl mitig impact earn
pay debt therebi reduc interest expens realiz addit revenu cost
synergi bard acquisit
term bard acquisit manag continu feel confid abil
achiev million cost synergi novemb becton manag
quantifi potenti revenu synergi associ bard acquisit
million
possibl question manag
optim leverag structur compani
compani achiev optim leverag ratio view
outlook capit deploy compani revert aggress
strategi look tuck-in deal go forward
expect meaning increas dividend
transform portfolio past five year becom larger
divers med-tech compani march becton dickinson complet
billion acquisit carefus ad infus pump medic manag
medic suppli portfolio decemb complet
billion acquisit bard ad peripher intervent surgic access
urolog product mix acquisit becton lever complet
transact move rapidli de-lev afterward end septemb
becton gross leverag becton goal reduc debt level
tuck-in acquisit central bard strategi becton state continu
look supplement legaci bard busi tuck-in deal juli becton
acquir tva medic develop minim invas vascular access product use
hemodialysi compani main product everlinq endoavf system
adjac opportun read-thru other
possibl question manag
reason chose exit bd simplist gener
inject program year ago sinc seem like logic adjac
attract market opportun note read-thru baxter
expand gener inject busi
infus solut distribut agreement freseniu proceed
met expect and/or greater opportun ahead
pro con enter intraven solut market
given leadership infus system today note relev
would consid broaden busi diabet care includ
believ becton manag offer commentari relev compani
insofar enter exit market opportun past year
provid insight opportun challeng respect area
bd announc program call bd simplist compani effort
enter pharmaceut manufactur take advantag signific
opportun gener inject product becton develop program
year prior announc north carolina plant approv fda
subsequ year becton receiv approv seven drug ready-to-
administ pre-filled glass syring howev becton sold busi freseniu
kabi state believ freseniu kabi logic owner given exist
capabl inject note becton acquir carefus thu decis
exit may also relat bandwidth chang strateg direct
manag focu success integr
along sale bd simplist program freseniu kabi becton enter
year suppli distribut agreement freseniu kabi would suppli bd
portfolio intraven solut earli becton note start ship iv
solut custom partnership freseniu believ revenu
associ distribut agreement minim fiscal
us infus solut market domin three playersbaxt icu medic
legaci hospira braun market suppli shortag number
year owe manufactur challeng encount three compani
baxter icu medic infus pump offer custom braun
offer pump unit state significantli smaller share market share
larger outsid us note senat letter address ftc chairwoman edith
ramirez date octob report compani attempt
tie contract pump dispos set along solut practic could
scrutin depart justic
possibl question manag
lesson learn carefus deal term
cost revenu synergi appli applic bard
transact make bard similar make differ
bard acquisit integr perform rel initi
expect area perform better wors
confid abil achiev cost synergi
million could see greater synergi similar carefus deal
million
step-down tax rate fiscal reflect tax synergi
associ bard could addit tax rate reduct
confid abil achiev revenu synergi million
revenu synergi term product
decemb acquir bard billion cash stock
becton state strateg rational deal includ acceler end-to-end medic
manag infect prevent creat new opportun across rang
clinic impact segment leverag bd global capabl creat new
opportun benefit combin compani product portfolio
onset bard deal becton estim million cost synergi
opportun view market expect becton overachiev target similar
carefus deal onset carefus deal becton estim cost synergi
area million though becton subsequ rais forecast achiev
cost synergi run-rat million septemb
deal model forecast provid street becton includ revenu
tax synergi though note possibl quantifi novemb
becton gave initi view potenti revenu synergi indic believ
million achiev revenu synergi expect come
three area expand vascular access portfolio stronger global surgic
offer global scale geograph expans becton also expect tax rate
lower fiscal versu fiscal realiz tax synergi
see benefit geograph mix
peripher intervent opportun risk
possibl question manag
signific growth driver drug-coat balloon dcb franchis
context sustain bard legaci busi rate
take recent clinic data releas below-the-kne btk
patient level confid market size bard
previous million opportun
view pend competit boston scientif ranger
abbott/surmod surveil drug-coat balloon market
view drug-elut stent peripher indic could
signific headwind bare stent and/or drug-coat balloon busi
graft chronic dialysi product endovascular fistula creation devic
current
one bard key product lutonix drug-coat balloon lutonix drug
indic percutan translumin
angioplasti de novo restenot in-stent restenot lesion mm length
nativ superfici femor poplit arteri refer vessel diamet mm
novemb becton announc clinic trial data studi lutonix below-the-kne btk
indic europ canada australia lutonix commerci avail
use btk arteri associ critic limb ischemia cii sinc bard submit
pma fda approv expect bard estim
market opportun associ btk indic around million total
opportun dcb excess billion
estim global dcb market million becton disclos
amount dcb sale estim sale million rang
market dcb leader estim sale similar becton
player us market philip acquisit spectranet
acquir dcb program covidien part mandat divestitur associ
deal believ philip neglig market share outsid
unit state boston scientif ranger dcb approv ce mark sinc juli
boston scientif aim approv unit state abbott
laboratori also drug-coat balloon surveil develop
partnership surveil dcb like receiv european approv around
year end fda approv
system fda-approv superfici femor arteri sfa full poplit arteri
bard e-luminexx vascular stent indic treatment iliac occlus diseas
patient common and/or extern iliac arteri
compani pursu develop drug-elut peripher stent
cook medic privat cover receiv fda approv zilver drug-elut stent
novemb receiv fda approv eluvia drug-elut stent
septemb boston scientif approv base imperi trial result
show eluvia superior zilver term rate primari
patenc rate versu respect well significantli lower rate
possibl question manag
challeng around dose captur insulin pen technolog
lead repriorit product still viabl opportun longer
investor think near long-term market opportun
swatch
talk featur benefit swatch patch pump
product rel drug patch technolog market like valerita v-
go former j/calibra medic cequr onetouch via
make better product and/or one capabl greater adopt
look integr continu glucos monitor technolog onto
swatch patch pump
becton diabet busi repres approxim total compani sale
includ syring pen needl use inject insulin drug use
treatment diabet
throughout histori diabet area focu becton dickinson
compani explor way expand busi
earli becton dickinson interest blood glucos monitor
market januari compani announc two new fda-clear blood glucos
monitor product bd logic blood glucos monitor bd latitud diabet
manag bd also announc enter two separ unrel
strateg relationship eli lilli increas diabet care market
presenc respect term agreement
distribut co-brand version bd logic blood glucos monitor bd strip
compani collabor develop integr system respect lilli
term lilli use diabet sale organ provid target support
market introduct new bd latitud diabet manag system lilli
bd would jointli pursu futur opportun diabet diseas manag becton
endeavor blood glucos monitor continu decid septemb half
effort bd manag conclud futur outlook increasingli
competit market justifi level invest addit resourc
necessari continu right call view bgm market would
subsequ come intens price pressur owe medicar reimburs
becton also sought expand diabet infus set use
conjunct insulin pump deliv insulin becton collabor jdrf
develop bd flowsmart technolog featur side-port cathet design
improv insulin flow reduc number flow interrupt bd flowsmart
technolog approv canada januari april part
agreement bd commerci set infus set
recal due issu compon becton work redesign set howev
becton announc novemb would discontinu product redesign
provid level differenti set hope
becton also made effort partnership jdrf relat continu blood
glucos monitor well combin devic continu blood glucos monitor
infus devic bd perform trial use glucose-bind protein-
becton also work dose captur insulin pen product smart pen becton
product smartsens needl would flow-sens technolog would
abl captur amount insulin dose deliv product design
univers fit dispos insulin pen howev compani februari
announc made decis stop program reassess near-term
commerci opportun rather decid deploy resourc smart type
patch pump see comment would return back pen
program later date
becton also focus insulin deliveri system design type ii patient
patch pump swatch design adjust basil bolu rate patch
design wear becton state design product low cost
near price pariti current therapi pen novemb becton
comment track submit regulatori approv us eu
come month becton current plan swatch us launch around end
compani launch attempt launch insulin
patch technolog gear type ii patient popul
valerita current sell v-go wearabl insulin deliveri devic v-go once-daili
patch offer basal rate steadi rate insulin hour also abil
provid addit insulin mealtim click button v-go
classifi durabl medic equip reimburs medicar
part v-go first commerci unit state view
compani sale trajectori less market hope valerita
expect revenu million exit year
decemb gross margin approxim
cequr swiss compani also work commerci insulin
deliveri devic paq patch devic deliv basal bolu inject
insulin day paq devic receiv ce mark
 develop insulin deliveri patch target type patient
acquir patch-mak calibra medic target launch product
brand name onetouch via howev decid exit diabet devic
market place sold calibra asset cequr juli cequr expect
launch system new name mid devic three-day insulin
deliveri patch provid bolu insulin deliveri devic deliv on-demand
mealtim bolu unit increment hold unit fast-act insulin
possibl question manag
manag see sustain rate busi go
forward past year better-than-market taken
share infus pump pyxi busi perform market
would character competit dynam infus pump
competit disadvantag broad offer infus
solut would compani consid get infus solut
market meaning way agreement freseniu
dispens technolog infus system estim sale roughli split
two busi
dispens technolog busi includ primarili system sold bd
pyxi brand major sale unit state bd pyxi
medstat autom medic dispens system typic maintain
access nurs unit bd also sell system medic suppli manag
call pyxi supplyst pyxi signific market share posit like
greater medic manag unit state main
competitor outsid unit state bd also offer rowa robot
medic storag retriev system retail hospit pharmaci
infus system includ infus pump sold hospit ambulatori
surgeri center transport servic becton largest instal base larg
volum pump unit state alari system primarili sold
unit state smart pump system allow simultan iv medic
fluid administr multipl deliveri modul syring pump larg volum
pump patient control analgesia pump pump use dedic
dispos administr set thu becton benefit sale pump
up-front enjoy long-term revenu stream dispos outsid
unit state becton market caesarea medic electron pump infus
syring expand bd busi ambulatori home specialti acut
care infus pump unit state becton dickinson primari competitor
infus pump baxter baxter recent launch new infus
possibl question manag
would manag will spin divest diagnost system
key new system new assay launch expect
next year
preanalyt system includ blood collect product system
product sold hospit laboratori clinic
diagnost system includ autom blood cultur tuberculosi
diagnost assay liquid-bas cytolog system cervic cancer screen
blood cultur busi largest part diagnost includ compani
flagship bd bactec system bd molecular platform includ bd bd
bioscienc includ fluorescence-activ cell sorter analyz reagent
molecular index next-gener sequenc sampl prepar genom
diagnostic/monitor reagent analyz product typic sold
pharmaceut biotechnolog compani well academ govern
institut research clinic tool use studi cell cell
compon aid discoveri develop new drug and/or improv
diagnosi manag diseas
co
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight believ bd
success integr bard achiev plan
synergi though market alreadi appreci
base success integr carefus
ep recalibr think
street forecast may still high
see upsid near-term enough
warrant chang view rate ew
upsid case could driven better-than-
bard acquisit improv overal
growth rate higher earn
downsid case could driven foreign
exchang stronger us dollar could pressur
expect sale legaci bard busi
slowdown emerg market growth
inabl off-set gore royalti
edward lifesci corp ew quarterli annual ep usd
consensu number thomson reuter receiv gmt
rate edward lifesci ew underweight price target
invest stanc turn follow
edward success tavr undisput there competit ahead
edward lifesci transform ugli duckl time spin-
baxter earli darl success transcathet
aortic valv program today edward leader transcathet valv market
best-sel transcathet aortic valv sapien howev compani
like face addit competit come year boston scientif
abbott plan enter market earli respect
transcathet valv survey suggest edward like lose market share
transcathet mitral tricuspid tmt valv could second act time
tell opportun unfold tmt repres area futur growth
edward compani multipl shot goal area sever
program seem promis still earli stage believ success
transcathet mitral valv requir ew share maintain current pe multipl
believ multipl may compress tavr slow ew share trade
ep estim believ multipl may compress given slower growth
greater competit transcathet valv market
sale product categori mo
sale geographi mo
transcathet heart valv less-invas transcathet aortic valv primarili sapien brand edward also self-expand
transcathet valv centera brand
segment includ surgic mitral aortic valv replac repair technolog
critic care product includ hemodynam monitor system measur heart function fluid
surgeri
trans-cathet heart heart valv barclay medic suppli devic
possibl question manag
think guidanc manag feel greatest
level confid achiev greatest amount
extent upsid forecast manag like reinvest
back busi could fall bottom line
investor think long-term growth profil compani
decemb investor day edward reiter guidanc includ
sale high end billion rang adjust ep edward
also provid initi guidanc gener bracket street consensu
edward expect sale billion underli basi
ep figur illustr edward specif guidanc rang
high end
end
sg sale
 sale
higher end
edward manag also provid long-term guidanc commentari analyst day
expect grow sale consider higher organ basi industri
averag expect mix effici lift gross margin longer term
percent sale declin expect futur sale growth exceed growth
edward continu expect invest clinic trial expand indic develop new
technolog sg spend percent sale expect stay roughli consist
project level long term edward leverag sale remain
disciplin control sg growth off-set addit invest
support innov net/net edward expect oper margin expand modestli
time tax rate expect increas though manag note less
predict due stock option account potenti polici chang
possibl question manag
forecast tavr market doubl much growth
come increas awar new patient versu convert patient
surgic penetr rate forecast tavr versu surgeri
thought like outcom low-risk trial
result market expect superior
sale centera track europ abl obtain
premium price across variou market
centera allow gain share self-expand valv
cannib market share
strategi roll sapien ultra europ well unit
forecast market share loss go forward boston
scientif launch lotu edg acur tavr valv
europ us forecast abbott portico valv
edward tavr busi repres approxim total sale
engin growth almost decad
edward expect tavr market continu grow doubl size
billion impli compound-annual-growth-rate driven indic expans increas awar
put take edward tavr busi
look ahead edward tavr busi like tailwind also
headwind
indic expans edward two trial underway could pave way
indic expans first trial low-risk trial evalu
safeti effect sapien valv versu tradit surgic aortic valv
replac savr patient symptomat sever calcifi aortic stenosi
low oper risk data trial expect present
american colleg cardiolog annual meet march manag
expect posit data expect fda grant low-risk indic late
also expect releas interim result low-risk studi
confer well second trial earli tavr trial enrol
patient sever aortic stenosi asymptomat studi
enrol earli decemb expect complet enrol
patient random tf-tavr arm clinic surveil primari
endpoint superior composit all-caus death stroke unplan
edward new tavr introduct edward receiv ce mark european approv
centera self-expand valv februari roll product
control manner edward price valv premium sapien
competit product edward also receiv ce mark sapien ultra valv
novemb though note also launch product control
roll-out edward unabl launch sapien ultra germani
enforc patent infring injunct sapien ultra edward next-gener
balloon-expand valv includ improv skirt design intend improv
paravalvular leak promot tissu in-growth system also on-balloon
deliveri system expand sheath edward receiv fda approv sapien
ultra end decemb
increas competit look ahead edward face increas tavr competit
boston scientif abbott laboratori boston scientif expect relaunch
lotu edg europ receiv fda approv boston scientif
also expect receiv ce mark acur includ advanc pvl
seal technolog also file two trial fda
first one repris iv studi plan use pursu us approv
lotu edg intermediate-risk tavr patient second one acur
studi intermediate- high- extreme-risk tavr patient use
support acur us approv abbott expect data portico us
trial present meet march portico trial includ
high risk extrem risk patient random either portico valv
commerci avail valv edward sapien corevalve/evolut
abbott also evalu next-gener flexnav deliveri system addit
patient abbott plan launch portico unit state earli
also continu develop next gener tavr devic
possibl question manag
thought need cerebr protect system
view
lack cerebr protect system competit
past concern regard incid stroke associ tavr
procedur sever compani develop cerebr embol protect system
design filter captur remov and/or deflect embol debri tavr
edward acquir embrella cardiovascular march million embrella
cardiovascular develop embrella embol deflector
design deflect embol materi transcathet valv procedur embrella
system receiv ce mark may edward commerci devic
unit state edward posit cerebr protect system compani
sure whether materi improv sapien perform given stroke rate
acquir claret medic august million up-front cash
million reimbursement-bas mileston payment claret medic sentinel
cerebr protect receiv ce mark fda clearanc
sentinel filter captur remov embol debri releas tavr
center medicar medicaid servic grant new technolog add-on
payment design sentinel took effect octob
possibl question manag
risk see patent litig case
would will settl patent litig much
think could cost compani
patent litig common area healthcar product includ medic
edward involv patent infring suit past success
litig regard andersen patent april district court
grant edward preliminari injunct limit sale corevalv system
unit state may edward settl outstand patent
litig term cross-licens agreement agre pay
edward up-front payment million agre pay quarterli licens
royalti payment million april
edward also entangl patent litig relat transcathet
valv unit state well intern court
us litig file patent infring case edward april
alleg sapien valv infring patent relat
adapt seal technolog june edward file counterclaim alleg
lotu infring three patent own edward octob edward file
petit interpart review ipr patent subsequ grant
march us patent trademark offic uspto found boston scientif
patent invalid boston scientif file appeal may decemb
juri district court delawar determin boston scientif
patent valid edward sapien valv infring patent
juri award boston scientif million infring damag
addit damag interest incur would determin
court post-trial motion juri also found edward spenser patent
valid lotu
infring edward expect pay damag uspto deem patent
invalid edward plan appeal verdict edward also su boston scientif
alleg watchman left atrial appendag closur devic deliveri system
infring patent own edward
germani boston scientif file patent infring action germani
edward alleg sapien sapien ultra devic infring patent
own march german district court rule sapien
infring boston ep ep patent
entitl enforc injunct sapien sale germani
upon payment million bond patent yet elect
edward appeal decis file opposit european patent offic
challeng valid patent august boston scientif
file preliminari injunct request relat sapien ultra octob
court found sapien ultra infring patent grant
injunct subsequ enforc novemb edward receiv
ce mark approv sapien ultra note could roll-out product
germani second largest tavr market due injunct german court
hold full hear merit disput
unit kingdom novemb edward file lawsuit sadra medic
boston scientif seek declar uk nation patent correspond
aforement patent invalid revok edward later ad uk
nation patent relat patent march uk patent court rule
patent invalid patent valid infring
court rule boston scientif entitl injunct sapien
sale uk stay injunct pend appeal may uk patent
court confirm injunct stay month juli boston
scientif file anoth suit edward alleg infring patent
possibl question manag
assumpt billion tmtt market expect
sale ramp mitral repair replac well tricuspid repair
play primarili mitral repair sale forecast expect
mitral market split term repair versu replac
tmtt program feel optimist today
level confid achiev million tmtt sale goal
latest updat cardioband suppli issu
product full transfer exist edward manufactur locat
see potenti timelin us market cardioband
pascal sapien evoqu long expect clinic trial
enrol take might studi endpoint
demograph suggest transcathet mitral tricuspid therapi tmtt market could
larger tavr market edward estim million patient
us alon moder sever mitral regurgit mr tricuspid regurgit
tr moreov estim today patient signific mr tr
treat us edward estim tmtt global market opportun could
billion size reach billion frame refer estim
abbott transcathet mitral valv repair mitraclip sale roughli million
around million edward target million tmtt
sale
edward activ research transcathet mitral valv therapi date back
least earli edward acquir percutan mitral valv repair program
jome februari even acquisit pvt complement
exist program edward also acquir asset percutan mitral valv
program sinc edward acquir cardiaq valv technolog
valtech cardio harpoon medic acquisit valtech
one approv deviceth cardioband system receiv ce
mark european approv septemb
edward current four transcathet mitral valv program develop
three transcathet tricuspid program develop summar figur
edward transcathet mitral tricuspid valv program
statu decemb
transcathet devic focus reduc mitral
regurgit annular reduct
mitral valv leaflet repair system includ
spacer paddl clasp
mitral valv replac system leverag
edward sapien aortic valv platform
incorpor dock station design
built learn experi forti
intern program cardiaq acquir program
 activ pivot trial current paus
 eu launch expect
 us pivot clasp iif fmr initi expect late
 earli feasibl studi us
 initi pivot trial late
 continu earli feasibl studi
design implant techniqu use
cardioband mitral system
 ce mark april
 activ tr pivot trial initi late
 tricuspid earli feasibl studi enrol
repair system consist foam-fil polym
balloon spacer rail anchor right
 return earli feasibl studi follow system
cardioband annual reduct system receiv ce mark mitral repair
tricuspid repair edward believ cardioband sale could reach
million howev manufactur suppli constraint decis shift product
anoth edward facil result lower sale estim tmtt sale like
million rang edward anticip higher sale suppli
decemb edward announc paus enrol cardioband
activ mr us pivot trial evalu trial design light abbott mitraclip
result activ trial origin design includ patient clinic
signific function mitral regurgit patient would random receiv
either cardioband system plu guidelin direct medic therapi gdmt gdmt
alon primari outcom measur preval mr hierarch
comparison devic control group includ time cardiovascular death number
heart failur hospit improv mwt distanc meter kccq
number point improv year
edward expect initi us pivot trial cardioband use treat tricuspid
regurgit activ tr late
pascal system transcathet mitral valv leaflet repair system includ
spacer paddl clasp mitral valv leaflet ce mark trial
clasp underway edward anticip eu launch studi single-
arm studi includ patient edward anticip data ce mark trial
avail either confer march europcr confer may
compani earn call edward announc receiv approv begin
clasp iid us pivot trial studi enrol least patient symptomat
primari degen mitral regurgit deem candid mitral
valv surgeri patient select criterion consist current label indic
mitraclip pre-coapt trial random edward pascal abbott
mitraclip edward also evalu patient suitabl pascal
separ arm studi
edward also plan pursu clasp iif fmr pivot trial would evalu
patient secondari function mitral regurgit edward expect initi
trial late would anticip trial would also random mitraclip
would anticip mitraclip gain label indic function mr base coapt
studi result
edward two program develop area transcathet mitral valv
replacementth sapien platform base sapien tavr platform evoqu
base legaci intern forti platform acquir cardiaq platform
platform design use via transfemoral/transept approach earli
feasibl studi valv platform underway edward expect initi us
pivot trial sapien late
possibl question manag
investor think manag alloc capit near
intermedi term
investor expect continu share repurchas activ primari use
free cash flow
structur heart failur outsid heart valv area interest
regard capit alloc edward first prioriti invest intern innov
program second supplement intern invest minor
invest novel technolog excess cash use repurchas share
septemb edward million total debt million cash
cash equival includ long-term invest includ million
acceler share repurchas edward note repurchas million year
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight believ sale growth like
slow edward face competit transcathet
aortic valv tavr expect limit leverag
edward invest transcathet mitral valv
tmvr/r opportun sale ep estim
street tmvr/r repres potenti
second act still risk like
upsid case may driven better-than-
expect tavr sale greater leverag
stronger uptak tmvr europ faster-
than-expect time tmvr/r product
downsid case may driven delay
inabl commerci tmvr/r technolog
slowdown tavr sale due market slowdown
and/or competit pressur fx rate
greater expens support tmvr/r
hill-rom hold inc quarterli annual ep usd
consensu number thomson reuter receiv gmt
lack convict sustain sale acceler
rate hill-rom equal weight price target invest stanc
turn follow
hill-rom diversifi portfolio past five year hill-rom
improv diversif busi less expos hospit capit
equip trend encourag compani futur strategi like
continu approach
underli sale growth may requir invest hill-rom core
sale growth remain level past three year fiscal
hill-rom estim sale core basi adjust
fx acquisit divestitur exit non-strateg assets/product line level
growth despit increas contribut new product long-rang plan
hill-rom expect core revenu growth acceler closer
believ risk acceler view addit invest
 may requir achiev higher growth profil weight averag
market growth rate compani around
sale product categori
sale geographi
surfac softwar solut
segment includ patient monitor diagnost product respiratori health product design
treatment environ rang primari care home care
product segment includ oper room capit equip like surgic tabl light oper
room posit devic along dispos product like scalpel blade skin marker integr tabl
motion surgic tabl pair da vinci xi robot key product segment
patient support line barclay medic suppli devic
possibl question manag
mr groetalaar view compani sinc join organ
posit neg find sinc join
mr groetelaar believ add compani strateg vision
ms bodem
impress hill-rom financ
organ strength ms bodem bring hill-rom
manag strategi
turn around perform
intern region drive greater growth develop
greatest potenti
view current spend hill-rom need increas
alloc order acceler core busi
manag believ increas activ need help
acceler sale growth profil compani
john groetelaar appoint presid ceo hill-rom effect may
recent serv execut vice presid presid becton dickinson
intervent segment join decemb follow acquisit
 bard inc mr groetelaar spent previou year number role
bard includ group presid among respons
improv bard emerg market exposur emerg market increas
total sale acquisit prior bard mr
groetelaar work guidant
barbara bodem appoint senior vice presid cfo hill-rom effect
decemb ms bodem join hill-rom serv
senior vice presid financ past three year prior ms bodem
work hospira vice presid global commerci financ well eli lilli
held varieti financ role includ serv cfo
lilli oncolog
hill-rom revenu current heavili skew market
revenu emerg market mr groetelaar note see under-penetr
latin america asia pacif specif two region repres
headwind fiscal larg due inventori manag issu compani
make improv inventori manag system region
complet complet fiscal hill-rom key product
regist latin america asia pacif region limit impact
 expens percent revenu declin
annual current guidanc fiscal increas
larger percentag spend shift toward project front
spend relat centrella launch declin long-term manag view
 margin appropri
possibl question manag
discuss focu capit alloc go forward specif regard
 focus tuck-in larger deal new adjac
area less attract
septemb hill-rom million cash equival
million total debt net leverag past sever year primari use
free cash flow de-lever septemb acquisit welch allyn left hill-
rom net leverag take opportunist approach
acquisit compani note pipelin mostli tuck-in bolt-on
opportun also acquisit capac compet larger transact
estim acquisit capac approxim million
possibl question manag
confid guidanc area feel
least confid deliv
expect impact outlook
investor think long-term growth profil compani
anyth chang long-rang plan tax
drive core growth higher rang given compani
histori grow core
novemb hill-rom provid long-rang plan lrp includ sale
growth margin ep aspir manag subsequ updat
lrp reflect tax reform legisl
revenu exclud foreign currenc divestitur exit non-strateg asset third-parti rental third-
manag expect core revenu defin revenu exclud fx acquisit
divestitur exit non-strateg asset acceler compound-annual-growth-rate
fiscal revenu constant currenc basi
hill-rom estim core revenu hill-rom expect revenu growth
acceler driven steadi cadenc new product partnership
fiscal hill-rom expect constant currenc growth core revenu
growth definit core revenu exclud specialti intern
oem busi benefit core growth rel past definit hill-rom
expect oper margin expand improv occur
gross margin hill-rom expect adjust tax rate
includ benefit stock base compens hill-rom expect adjust ep
rang increas year-over-year basi adjust
benefit relat stock base compens fiscal ep growth
fiscal closer ep guidanc yet reflect adopt
account standard updat revenu contract custom
plan adopt modifi retrospect basi begin fiscal
manag estim adopt may result reduct revenu
million ep fiscal expect materi impact
growth rate fiscal word base year reduc
current stated/impli dollar rang may reduc well
hill-rom forecast report revenu growth approxim constant
currenc growth approxim core growth approxim adjust ep
expect rang adjust benefit stock-
base compens guidanc impli adjust ep growth
note guidanc yet reflect adopt
possibl question manag
key new product drove new product sale million
fiscal ahead compani million guidanc much
pipelin addit vs cannibalist
look ahead new product hold greatest growth potenti
hill-rom gener million new product fiscal hill-rom initi
guidanc new product contribut fiscal million howev
compani exceed level achiev million fiscal hill-rom guidanc
includ million new product contribut lrp fiscal estim
hill-rom defin new product launch sinc product alreadi
launch includ connex monitor vision screener retinavu vesivest
trusystem surgic tabl linq mobil product expect
approv next two year includ next-gener surfac watchcar
assess revit vital sign patch next-gener respiratori therapi
centrella smart medsurg bed system within pss key driver sale
centrella bed launch centrella launch fall manag
believ acceler replac cycl us bed design new
technolog enabl nurses/physician better prevent patient fall
enhanc surfac help reduc pressur ulcer skin deterior
issu centrella gener million revenu sinc launch
centrella sale account approxim us medsurg revenu
would expect continu strength us fiscal also believ could
growth intern hill-rom expand sale focu middl east
retinavu retinavu network welch allyn acquir hubbl telemed januari
hubbl telemed call retinavu network combin
softwar specialist network allow point-of-car retin scan detect
diabet retinopathi encrypt scan sent state-licens board-certifi
ophthalmologist turn send physician diagnost report fundu imag
code recommend referr care plan scan complet
process typic complet minut retinavu imag launch
march hand held fundu camera low power microscop camera
use photograph retina cost approxim less tradit
fundu camera manag size us diabet popul
approxim million believ retinavu could becom million-plu per
year product hill-rom announc new partnership siemen healthin
market leader test us retinavu imag includ suit
diabet instrument provid proactiv test treatment singl visit
product gener revenu sale devic well fee per
screen fiscal hill-rom invest person dedic sale team
retinavu note devic placement increas doubl digit year
compani launch next-gener devic fiscal
improv eas use
vision screener vision screener handheld devic design
quickli detect vision issu patient young six month old hill-rom
focus market effort improv earli detect amblyopia
vision disabl children
integr tabl motion hill-rom receiv clearanc
offer integr tabl motion itm da vinci xi surgic system us
januari trusystem design connect da vinci xi
surgic system order allow dynam patient posit surgeri
part agreement intuit surgic intuit offer itm softwar
part da vinci xi sale process softwar sale success hill -rom
sale rep respons close final sale itm tabl current
approxim da vinci xi robot sold itm softwar
high convers rate manag note still larg uninstal base
present opportun itm gener approxim million
ad overal growth itm sale grew
manag expect increas domest da vinci xi penetr well
europ japan
equal weight view compani may
continu struggl increas core sale growth
 may necessari rate
stock equal weight
rate driven new product introduct better-
than-expect margin improv
downsid case driver includ challeng
hospit capital-expenditure environ inabl drive
acceler top-lin growth increas
competit pressur dilut
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
medtron plc quarterli annual ep usd
consensu number thomson reuter receiv gmt
rate overweight price target invest stanc
turn follow
believ execut plan view execut
stori compani mix track record histor believ
manag tool incent get right go forward
mid-single-digit sale high-single-digit ep growth seem like expect
medtron top-lin growth come combin end-market growth along
benefit new technolog june investor day manag
provid expect growth target organ sale growth
annual oper margin expans constant currenc basi ep growth
least believ medtron achiev exceed baselin goal
growth reason price high sale growth profil
other sector also high valuat multipl
growth profil believ share attract price believ
trade closer sector histor averag expect pe multipl
expand
sale product categori
sale geographi
product includ devic design diagnos treat manag heart rhythm disord heart failur
pacemak implant cardiovert defibril icd cardiac resynchron devic crt-p/crt-d
implant cardiac monitor left ventricular assist devic lvad
coronari structur heart product treat coronari arteri diseas heart valv disord includ coronari stent cathet
transcathet aortic valv replac surgic ablat product brand includ corevalv line
transcathet aortic valv resolut drug-elut stent
aortic peripher vascular aortic peripher vascular product treat aortic diseas peripher vascular diseas venou diseas via
graft stent system drug coat balloon carotid arteri embol protect
product includ surgic product stapl devic vessel wound closur electro surgeri
product divis also includ hernia gynecolog product
respiratori monitor airway manag product devic minim invas gastrointestin
procedur treatment renal diseas
spinal implant treat degen disc diseas spinal deform spinal tumor fractur spine
stenosi spine also includ product facilit less invas thoracolumbar surgeri treat condit
cervic region spine biolog solut infus deminer bone matrix product
neurovascular product coil stent devic treat brain aneurysm stroke brain
modul product use treat parkinson epilepsi ocd neurosurgeri product includ
product treat ent diseas control pelvic gastric condit interstim system specialti
surgic product surgeri system aquamanti system
spinal cord stimul implant drug infus system chronic pain intervent product
diabet product design type type ii diabet patient includ insulin pump continu glucos
monitor system diabet manag softwar minim line insulin pump major brand
busi segment
possibl question manag
put take fiscal could recent fx
movement impact outlook
investor think long-term growth profil compani
driver deliv organ sale growth
extent upsid organ growth rate would manag
inclin let flow bottom line achiev ep growth
excess would manag look reinvest upsid back
analyst day june manag provid updat longer-
term expect manag expect drive least organ revenu growth
incorpor view develop market grow emerg market grow
low doubl digit busi group expect cardiac vascular group cvg
minim invas therapi group mitg restor therapi group rtg grow
line corpor averag diabet expect grow faster manag
expect sustain annual underli oper margin expans rang
net/net manag expect adjust ep growth
fiscal expect organ sale growth high end
rang adjust ep rang fiscal compani
expect organ sale growth high end rang adjust ep
rang would note rel tough comparison
constant currenc revenu growth
possibl question manag
revenu impact anima partnership break
across three revenu opportun
time achiev factori calibr elimin finger stick
confirm guardian cgm system
follow earlier-than-expect approv june launch medtron minim
hybrid close loop type insulin system expect diabet group
associ guardian connect continu glucos monitor cgm sensor well
shipment relat compani prioriti access program limit initi uptak
instead doubl digit growth diabet revenu declin low-single-digit
issu prove transitori diabet segment sale inflect
grow respect
manag believ roll-out still earli inning expand indic
market penetr drive growth also see increas cgm
sensor util attach rate driver continu sale growth go forward
expect launch minim new ou market
releas next gener sugar iq algorithm expect launch
advanc hybrid close loop system design improv time-in-rang
anima partner choic
octob anima johnson johnson announc exit north
american pump busi name partner choic anima
patient approxim three opportun monet
opportun record revenu associ suppli patient current warranti
consum convert patient warranti pump
updat in-warranti anima patient pump
also launch first stand-alon gcm guardian connect sugar iq
june cgm system measur glucos level everi five minut display
associ mobil app current system still requir finger stick calibr
well finger stick confirm wherea compet cgm system abbott
freestyl libr dexcom longer requir finger stick compani expect
roll multipl advanc continu glucos monitor cgm technolog
possibl question manag
time next-gener evolut tavr devic
differenti horizon platform evolut platform
latest updat enrol apollo trial
expect transept intrepid devic integr
seek expand corevalv evolut indic use low surgic
risk patient popul interim data expect releas american colleg
cardiolog meet march continu invest next-
expect launch evolut next gener tavr valv lower
profil improv placement also work new platform
name horizon product expand indic ensur
continu double-digit growth tavr busi forese futur
also develop transcathet system treat mitral valv octob
receiv fda approv start apollo transcathet mitral valv
replac trial evalu intrepid valv enrol underway site
activ continu work toward incorpor transfemor transept
deliveri system accord clinicaltri gov studi enrol particip
primari outcom measur
all-caus mortal stroke reoper
reintervent cardiovascular hospit year moreov estim
primari outcom complet date project octob suggest potenti
approv still sever year away
possibl question manag
view competit landscap surgic robot
differenti medtron system other
expect mazor robot spine platform acceler growth
medtron legaci covidien robot surgic platform date back januari
past sever year compani devot signific amount resourc
bring product market timelin system slip compani
note delay work system featur current timelin
advanc system clinic fiscal launch occur fiscal
essenti one year later initi plan johnson johnson also target
market launch verb surgic platform partnership verili alphabet/googl
unit kingdom base cmr surgic recent enter market decemb
launch first train program florida compani versiu system
robot surgeri market pioneer sale expect approach
billion year refinitiv estim
decemb close acquisit remain stake mazor
billion total gross deal valu billion mazor robot
guidanc system spinal surgeri expect next gener mazor
stealth robot navig platform
acquisit expect modestli dilut fiscal adjust ep
given current strength underli busi compani expect absorb
dilut
cardiac rhythm heart failur
possibl question manag
manag long term view growth rate us high power
icd/crt-d low power pacemaker/crt-p implant market
manag view abil sustain market share
outlook atrial fibril franchis
outlook heart failur left ventricular assist devic lvad
cardiac rhythm heart failur largest sub-seg within cardiac vascular
group cvg repres total compani sale expect market
grow low-to-mid singl digit next five year though believ well
posit grow busi mid-single-digit rang continu leadership
within atrial fibril diagnost well return core implant
busi growth
receiv fda approv micra leadless pacemak april though last
year first full fiscal year reimburs exit year sale
annual well million revenu product today individu
need single-chamb pacemak estim pacemak popul
howev compani develop next-gener version expand
address market entir pacemak commun micra one-tenth size
tradit pacemak implant via minim invas approach
target releas micra av end fiscal expand
market applic half market
possibl question manag
find trial use design on-m
potenti timelin data releas fda approv renal
renal denerv potenti back five year ago signific
enthusiasm around multi-billion dollar market prospect renal denervationth
ablat renal arteri reduc blood pressur level patient hypertens
three major cardiac compani boston scientif st jude renal
denerv program place acquir program million
ardian deal boston scientif acquir million plu
mileston million vessix deal market enthusiasm significantli
cool announc januari medtron symplic trial
fail meet primari endpoint went back draw board
attempt anoth shot redesign symplic spyral system latest
european data use symplic spyral system seem encourag though time tell
multi-billion opportun resurrect
novemb began fda-approv clinic trial evalu
symplic spyral renal denerv system patient high blood pressur
alreadi prescrib anti-hypertens medic trial random sham-
control studi random patient center japan
europ austrailia canada patient follow three year primari safeti
endpoint includ major advers event one month new renal arteri stenosi
six month primari efficaci endpoint ambulatori blood pressur six
month subject prescrib stabl regimen three anti-hypertens
medic includ diuret calcium channel blocker ace/arb inhibitor beta
possibl question manag
outlook brain therapi busi
key new product manag feel could signific
contributor growth
signific could cranial mount db system
medtron brain therapi divis grew constant currenc basi fiscal
growth driven larg success sell capit equip
strong portfolio neurovascular devic also record revenu mazor
robot guidanc system within brain therapi demand stealthstat
navig o-arm imag also driven growth
medtron neurovascular portfolio driven mid-teen high twenti growth
sever year strength attribut solitair platinum stent acut
ischem stroke neuro access product coil intrasaccular therapi well flow
divers product compani expect launch react cathet riptid
aspir system next-gener solitair revascular devic
possibl question manag
program place drive margin expans
june investor day manag provid expect annual
oper margin expans constant currenc basi heart
expans target enterpris excel program announc januari
enterpris excel program aim reduc cost billion fiscal
increment annual gross run-rat save expect
million rang fiscal period identifi three area
global oper strategi would includ standard best practic
optim qualiti deliveri cost cash flow across manufactur suppli chain
administr facil also includ network optim strateg sourc
save gener vector primarili seen cost good sold
help off-set annual price pressur seen across busi
global function optim includ transform improv product
employe experi area like financ human resourc legal inform
technolog sourc qualiti aim enhanc leverag global
oper model system like share servic save materi cost
good sold sg line
global commerci optim would includ save target evolv
go-to-market model enhanc autom sale process transact
improv product consolid certain common oper
system save vector primarili seen sg line
possibl question manag
manag look opportun today rel
past what chang anyth
invest commun expect tuck-in acquisit would
manag will larger transact
manag state target return least free cash flow
sharehold via share repurchas dividend year-to-d paid
billion dividend billion share repurchas total pay-out ratio
respect acquisit seem manag focus tuck-in acquisit
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ
number new product across busi
allow sustain mid-single-digit growth
expect leverag provid
least high-single-digit ep growth believ
stock valuat still attract despit recent
appreci share
upsid case driver includ success
deploy market share gain key area
cardiovascular structur heart surgic
neurostimul greater margin expans
expect
inabl receiv product approv market
share loss key categori dilut deal
stryker corp quarterli annual ep usd
consensu number thomson reuter receiv gmt
rate overweight price target view
diversifi growth stori remain firmli intact believ stock warrant premium
valuat overweight rate base view
sustain above-sector-averag revenu growth believ
attract mix busi thank acquisit strategi past decad
compani built attract franchis area orthoped medsurg equip
neurotechnolog spine given mix busi product
outlook believ averag revenu growth sustain
abil drive leverag bottom line long-term goal
includ commit drive least basi point oper margin
expans deliv floor target ep growth believ compani
cost transform program help achiev goal
durabl growth warrant premium valuat believ durabl
growth among highest within medic devic believ premium
valuat warrant
sale product categori mo
sale geographi
product includ partial total knee implant primari revis procedur cement
cementless product total knee arthroplasti
offer primari revis total hip replac product offer direct superior approach
instrument help spare muscl damag surgeri
trauma extrem product portfolio includ implant bone fractur bone plate bone nail
extrem arthroplasti product biomateri
includ imag system fluid manag product capit sale mako robot surgeri system
product includ power tool accessori surgic navig system wast manag product
endoscopi product includ laparoscop minim invas surgeri imag system along surgic tool
design procedur
includ emerg medic equip hospit patient transport equip intens care
stryker sustain categori includ reprocess remanufactur medic devic
segment includ neurovascular product focus treat stroke patient surgic tool neurosurg spine
ent procedur carniomaxillofaci product
spine product includ spinal implant instrument biomateri navig diagnost tool
possibl question manag
put take investor consid
investor think long-term growth profil compani
track reach high end organ growth guidanc
rang adjust ep guidanc rang compani yet
given formal guidanc manag note believ look
lot like re-affirmed expect see margin expans despit
dilut relat recent acquisit
possibl question manag
initi within ctg program drive continu annual
improv
introduc ctg program goal achiev
oper margin improv annual period program first
year product recal hurrican damag puerto rico dilut
acquisit novadaq neg impact compani abil achiev margin
expans target oper margin declin adjust
impact headwind achiev oper margin expans
year-to-d success expand oper margin despit
neg impact compani complet six acquisit
manag reiter expect see margin expans
possibl question manag
view competit environ hip knee
view zimmer biomet rosa depuy orthotaxi
robot system competit believ system could
strategi build upper extrem busi
view shoulder portfolio rel peer forese chang
level invest segment
stryker orthoped segment revenu repres total sale sale
organ basi maintain steadi mid-single-digit
high-single-digit growth larg due market lead growth knee busi
well consist growth trauma extrem unit hip knee market
typic refer larg joint market tend grow low-singl digit
trauma extrem market grow mid-singl digit
makohelp separ peer
acquir mako surgic corp decemb million repres
ev ltm revenu multipl ev ntm revenu multipl
mako rio robot arm system stryker mako approv partial knee
arthroplasti pka total hip arthroplasti tha time acquisit
receiv clearanc total knee tka applic initi
limit launch march full roll-out occur march
competit environ could becom challeng zimmer biomet
plan limit launch rosa robot platform depuy expect
launch orthotaxi platform
decis use cement cementless fixat tka debat sever
decad cement fixat associ high qualiti outcom long-term
follow-up studi osteolysi relat bone stock alter mechan stress due
implant/kne malalign bone/c interfac lead surgeon find new
design flaw plagu earli cementless tka implant nearli tka return
cement fixat osteoconduct surfac fixat technolog improv cementless
tka implant survivorship improv compar cement tka
launch tritanium cementless tibial basepl grown cementless
knee approxim total knee volum cementless tka implant carri higher
higher margin benefit major manufactur
cementless tka market sever year howev zimmer biomet current
soft launch cementless tibia knee implant depuy johnson johnson plan
launch cementless knee
extrem sub-seg steadi double-digit growth engin within
orthoped segment last five year much growth come build
foot ankl busi compani use acquisit memomet
catalyst set dedic foot ankl sale forc continu build
product portfolio intern develop small bone innov
also begun build dedic sale forc upper extrem portfolio
late focus build shoulder offer estim stryker
shoulder market share remain rel low believ catalyst
next leg growth extrem segment
possibl question manag
inning regard mako penetr
addit area within orthoped believ robot
believ place soft tissu robot platform within
stryker success mako platform total knee arthroplasti provid
compani market growth knee replac strong foundat
build broader orthoped robot platform
next sever year would expect continu build robot
focu hard tissu arena compani novemb investor meet
manag note initi project focus improv shoulder arthroplasti
spine surgeri mako technolog also complet initi homework
appli robot total ankl arthroplasti
regard entri gener surgeri robot manag note
hard tissu near-term focu view gener surgeri logic adjac
given would three larg medic devic player soft tissu robot market
view less like compani would look develop gener
surgeri robot intern stage would instead look acquir differenti
possibl question manag
trend hospit capital-expenditure market
near-term long-term market opportun novadaq
outlook product
gener plu organ growth medsurg segment last two
year driven intern product innov contribut acquisit
anniversari segment gener million revenu
repres sale sale constant currenc basi
organ
endoscopi sub-seg gener million sale repres
constant currenc growth segment growth recent year driven primarili
decemb launch aim surgic video platform next gener
surgic platform expect launch off-set declin sale
acquisit novadaq close septemb also
enhanc sub-seg organ growth profil
complet acquisit product billion april
sale total million consist dispos product focus reduc
hospit acquir condit never event icu medsurg hospit unit
set compani grow low-teen howev compani
sever recal lead declin sale juli recal one lot
comfort shield cloth subsequ expand juli receiv
warn letter relat oral solut august initi recal
specif lot oral product put temporari hold cloth-bas product
resum ship octob continu feel impact
recal sale declin year-after-year expect return growth
pre-recal level would expect return take sever quarter play
neurotech spine
possibl question manag
view neuromodul market logic
adjac expans
key new product launch neurotech franchis
rational go deeper spine market via
gener high-singl digit organ growth neurotechnolog spine
segment last three year larg driven strong product innov market
growth within neurotechnolog combin segment gener million
revenu repres total sale segment grew constant
currenc organ look ahead expect continu strong growth
driven neurotechnolog market segment also benefit contribut
entellu
neurotechnolog sub-seg gener million sale repres
constant currenc growth much growth neurotechnolog segment
attribut neurovascular product target coil acut
ischem stroke product growth also driven craniomaxillofaci cmf
product neuro power instrument
februari complet acquisit entellu medic
purchas price per share aggreg purchas price million
acquisit expand presenc nose throat ent segment
provid dedic ent sale forc believ entellu franchis
sustain growth high-teen
novemb close acquisit group hold ktwo
per share impli equiti valu approxim billion enterpris
valu approxim billion gener million ltm revenu
impli ev ltm sale multipl consist view spine core
busi given largest orthoped sub-seg meaning overlap
neurotechnolog busi acquisit bolster product portfolio
complex spine spine deform trauma tumor minim invas approach
possibl question manag
focu compani still primarili focus tuck-in
would open larger deal new adjac
 core growth strategi compani complet
acquisit sinc compani gener look tuck-in style deal addit
product technolog near adjac specif manag note
view neuromodul area interest sever year
focus continu increas dividend view share repurchas larg tool
off-set dilut
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ sustain
above-sector revenu growth profil see
multipl driver across three busi
believ deliv margin commit
goal least annual drive least
ep growth given outlook believ
premium pe justifi
growth greater success new product
greater success drive oper margin
downsid case driver includ slowdown
orthoped hospit capital-expenditure market increas
competit knee foreign exchang stronger
us dollar inabl drive margin expans
quarterli annual ep usd
consensu number thomson reuter receiv gmt
put take
rate equal weight price target maintain equal
weight rate believ
urolift provid uplift growth octob acquir neotract
billion transact acquir fast-grow high gross
sale expect grow estim million
sale believ potenti exceed million next five year
expect urolift lift core sale growth rate
revenu acceler proven difficult past three year
aim increas growth rate core sustain though
fallen short rang averag sale compound-annual-growth-rate look ahead expect
legaci busi remain around level growth addit
faster grow vsi neotract sale help lift overal growth
street ep estim may high believ fx rise interest
rate like headwind also believ compani like
continu invest behind growth opportun urolift improv core
sale product categori mo
sale geographi mo
product includ cathet relat devic posit use intraven medic administr
blood pressur measur draw blood sampl product primarili market arrow brand
divis includ product use intervent cardiologist intervent radiologist vascular surgeon
cathet devic treat coronari peripher vascular diseas bone marrow access system
hemodialysi cathet cardiac diagnost cathet includ busi segment
teleflex anesthesia segment includ pain airway manag product pain product includ epidur kit
peripher nerv block kit dispos pain pump airway manag product includ mask atom
devic endotrach tube laryngoscop
product includ singl use reusabl product ligat wound closur system
laparoscop surgic instrument port
categori includ single-us respiratori urolog intervent urolog product intervent urolog
includ urolift system acquir via neotract acquisit treat patient bph
possibl question manag
put take investor consid
investor think long-term growth profil compani
manag confid long rang plan lrp outlin may
drive confid legaci exclud vascular
solut neotract growth
driver long-term oper margin goal
may outlin long-rang plan lrp next three year
period expect averag organ constant currenc revenu growth
rate assum base busi grow rate
vascular solut acquisit add growth neotract add
lrp expect adjust gross margin continu expand
oper margin expand
expect constant currenc revenu growth organ
revenu growth low end expect gross margin
oper margin adjust ep expect
rang
possibl question manag
view market opportun urolift
urolift compar boston scientif rezum term efficaci
long-term result
urolift reimburs compar avail therapi
urolift minim invas technolog treat lower urinari tract symptom due
benign prostat hyperplasia bph urolift expect contribut per
year long-rang plan octob complet acquisit
neotract develop urolift system million up-front payment plu
million conting mileston
expect sale growth million level
believ highli like given momentum first nine month
year next five year believ urolift sale could grow roughli
million driven continu adopt aid recent inclus urolift standard
care option treatment enlarg prostat american urolog associ
aua clinic guidelin address patient popul larg incid bph
men men men age
us alon million men treat bph though initi focu
us opportun intern opportun equal larg intern urolift
sale primarili uk today though work reimburs
countri also submit shonin japanes registr worth note
mileston pay-out million base sale target million
risk forecast could competit minim invas bph market could
becom competit boston scientif rezum system rezum
fundament differ urolift urolift procedur perman implant
place hold open obstruct pathway block urin flow
minim invas transurethr outpati procedur rezum use water vapour remov
excess prostat tissu allevi obstruct flow rezum clear fda
though uptak rezum thu far limit reimburs
possibl question manag
pipelin product could help deliv top-lin growth
discuss rational acquisit manta vascular closur
devic essenti medic contribut
view market opportun repla
latest statu percuv still believ
manag goal acceler compani organ sale growth
rate higher mani year past four year averag howev
compani develop acquir sever product show promis potenti
octob acquir essenti medic million million
potenti sale regulatori mileston payment essenti medic develop manta
vascular closur devic design closur larg bore arteriotomi typic
associ transcathet aortic valv replac tavr endovascular aneurysm
repair evar devic receiv ce mark approv juli follow patient
min sec median sec low complic rate manta
vcd use case date expect receiv fda approv
safe manta trial singl arm patient trial primari endpoint
focus time hemostasi manag note believ tavr evar
opportun million
comparison across clinic trial tricki result previou trial compar
current larg bore vascular closur devic provid potenti opportun manta
take share view assum result fda studi line ce mark
studi abbott perclos proglid indic use access site femor
arteri use sheath access site femor vein use sheath
current primari vcd market larg bore arteriotomi perclos
proglid similar safeti data major complic rate mean time
hemostasi minut second patient requir secondari closur
method manual compress subcutan stitch requir two proglid
acquir repla part acquisit vascular solut product
develop armi armi sponsor clinic trial
treatment battlefield trauma emerg applic retain
commerci right repla
resuscit plasma requir stop uncontrol bleed prevent shock
compani estim civilian trauma patient militari patient
requir massiv transfus due hemorrhag
current civilian plasma stock typic store frozen requir minut thaw
thaw maintain hour shelf life dynam coupl urgenc
associ trauma case lead plasma wast approxim teleflex
expect civilian opportun sell em transport hospit
segment although view immedi opportun servic militari
market militari current freeze-dri plasma avail howev glass
bottl fragil militari medic transport repla packag freez dri
plasma polym bag store room temperatur reconstitut
steril water two minut
estim total market size repla approxim million
govern contract repres roughli million civilian use remain
million product receiv acceler bla approv pathway april
recent complet phase safeti trial expect submit final modul
bla submiss earli approv repla could potenti upsid driver
forecast compani note includ modest sale repla
lrp
percuv surgic system percutan approach access inner organ
tissu achiev via needl punctur laparoscop surgeri percutan
approach reduc number trocar medic devic function portal
subsequ placement instrument provid better angl surgeon
address surgic site minim trauma patient develop
percuv intern receiv initi fda ce mark approv
product launch protract manag initi thought addit
fda trial slower expect valu access committe process slow progress
compani issu voluntari recal multipl delay push return
product
possibl question manag
manag ideal leverag posit expect tuck-in
deal could anoth larger transact also like
recent year gener reli tuck-in acquisit drive top-lin growth
compani made two larg platform acquisitionsvascular solut
neotract may investor day note intend remain serial
acquir focu invest key diseas state market septemb
compani million cash million debt leverag ratio
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight believ neotract vsi
howev core growth rate struggl
improv howev ep estim
street believ fx rise interest rate
headwind given believ stock
fairli valu current level
upsid case could driven greater urolift
vsi sale greater improv profit
improv core busi sale growth
rate accret
downsid case could driven slowdown
urolift sale rel expect challeng
within core busi foreign exchang rate
stronger us dollar higher interest rate
quarterli annual ep usd
consensu number thomson reuter receiv gmt
rate zimmer biomet underweight price target revis
price target reflect lower target multipl ep vs
light uncertainti around pace transform invest stanc turn
follow point
modest sale acceler seem like zimmer biomet challeng
manufactur constraint due qualiti system remedi past year
half look ahead expect constraint eas provid zimmer biomet
opportun modestli acceler sale growth also believ number
new product help sale perform come year cementless
knee persona revis knee rosa robot applic though street
expect near term may high
prospect new ceo corpor strategi encourag view
bryan hanson appoint ceo posit posit believ bring
zimmer biomet new vision strategi long overdu
there like long road ahead manag character turnaround
restor compani end market growth rate two year process agre
howev ultim compani growth outlook defin end market
compet unfortun zimmer biomet like mean low single-
digit growth believ hanson overarch object acceler top-lin
growth mid-singl digit seem possibl increas
invest importantli activ portfolio manag view
transform need stock like see signific appreci
street expect may ok may still high
believ zimmer biomet may continu see margin pressur slight
improv ep estim line street
ep estim believ stock multipl unlik
expand significantli current level earn acceler
sale product categori mo
sale geographi mo
zimmer knee implant portfolio includ product instrument primari revis procedur
compani offer partial knee system total knee system person implant solut market
segment includ hip arthroplasti implant instrument primari revis procedur
sport extrem
product includ soft tissu injuri repair product sport medicin patient extrem repair replac
devic like plate bone nail shoulder elbow implant biolog solut enhanc recoveri
trauma surgeri
dental product includ dental implant system surgic kit surgic tool regen product
includ spinal implant devic design treat traumat injuri degen condit biolog solut
electron stimul product within spine divis cmf divis includ facial skull
reconstruct product product bone fixat stabil chest injuri cardiac surgeri
segment includ bone cement offic base technolog product like zimmer biomet spinalpak spinal fusion
possibl question manag
put take investor consid
investor think long-term growth profil compani
gross oper margin go time action
compani take achiev margin goal
put take behind achiev wamgr
zimmer expect constant currenc revenu growth adjust cash
ep expect rang compani provid
offici guidanc manag note expect achiev growth
weight averag market growth rate wamgr manag
also note fx act headwind disclos
termin bone cement distribut contract would neg impact sale
million per quarter
possibl question manag
statu remedi effort warsaw campu
back suffici suppli level product
outcom regulatori meet fda
late fda inspect zimmer biomet north campu manufactur facil
warsaw indiana issu fda inspect observ
inspect observ issu conclus inspect fda
investig observ condit may constitut violat food drug
cosmet fd act relat act april zimmer receiv anoth
relat north campu facil subsequ respond fda august
zimmer biomet receiv warn letter fda relat north campu
facil warn letter fda acknowledg progress made
zimmer biomet note outstand defici fda also propos regulatori
meet discuss propos correct
manufactur qualiti remedi effort initi affect zimmer biomet abil
produc adequ suppli product across knee hip busi unit
compani work improv suppli product anticip eas
constraint year earn call manag note qualiti
remedi longer restrict zimmer abil produc ship product longer
impact suppli recoveri compani product suppli situat continu
possibl question manag
statu rosa robot platform
would expect roll-out unfold
zimmer biomet acquir rosa robot system juli acquisit
med-tech sa french med-tech compani origin applic rosa spine
compani iter platform use total knee arthroplasti
earn call manag note compani complet five case australia
ahead schedul compani wait fda approv total knee
spine applic expect would carri limit launch
thereaft full launch schedul
possibl question manag
dental core part compani spine
appropri leverag level zimmer biomet posit
conduct
extent would compani will transact would
adjac white space rather tuck-in deal diversifi
capit alloc like critic longer term success zimmer biomet share
believ mr hanson look increas compani weight faster end market
manag note desir diversifi growth engin like categori
within sport extrem trauma set march wall street journal
report zimmer biomet retain advisor assess potenti divest
compani dental busi zimmer biomet hold consid sale dental
manag comment merit report
strategi activ portfolio manag uniqu med-tech good
compani strategi acquir compani potenti acceler
underli sale growth rate acquir cost-sav synergi think
med-tech landscap compani consid aggress activ portfolio
manag includ baxter avano formerli halyard health differ
compani zimmer biomet balanc sheet septemb
zimmer biomet net debt billion compani expect gener free cash
flow year tune billion billion last year small
amount earmark pay dividend million think much balanc
year like go pay debt net debt ebitda closer zimmer
biomet may look use cash flow purpos
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight view appoint
bryan hanson ceo posit catalyst chang
believ orchestr turnaround
howev believ transform need
like take multipl year sever new product
could help competit posit knee
impact like materi also
upsid case could driven improv
market trend orthoped greater success
improv price trend strateg
downsid case could driven inabl
receiv and/or execut new product approv
deterior price addit fda regulatori
exchang stronger us dollar dilut
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
